CD40LG and malaria: The first study showed a reduction in clinical malaria risk with asexual stage specific IgM, which persisted up to 12 months in children aged 5–14 years [18], while the second one did not show low susceptibility with asexual stage specific IgM in older individuals (3 months to 36 years) [77].